Age and comorbidity are determining factors in the overall and relative survival of patients with follicular lymphoma.
Age
Comorbidity
Follicular lymphoma
Prognosis
Survival
Journal
Annals of hematology
ISSN: 1432-0584
Titre abrégé: Ann Hematol
Pays: Germany
ID NLM: 9107334
Informations de publication
Date de publication:
May 2021
May 2021
Historique:
received:
17
11
2020
accepted:
18
02
2021
pubmed:
26
2
2021
medline:
27
4
2021
entrez:
25
2
2021
Statut:
ppublish
Résumé
Frailty and concurrent medical conditions are crucial factors in the management of follicular lymphoma (FL). We evaluated the impact of age and comorbidity on survival, causes of death, histological transformation (HT), and second malignancies (SM) in a large single-center series of grade 1-3A FL. We studied 414 patients diagnosed in the rituximab era, categorized into three age groups (≤60, 61-70, >70 years) and two comorbidity groups (Charlson Comorbidity Index, CCI, 0-1 and ≥2). Despite a similar cumulative incidence of relapse, older and comorbid patients had a lower 10-year overall survival (OS, 88, 65, and 41% for patients ≤60 years, 61-70 years, and >70 years, P<0.0001; and 76 vs. 51% for CCI 0-1 and ≥2, P<0.0001). In a multivariate analysis for OS, comorbidity retained its prognostic impact (HR=2.5, P=0.0003). The proportion of patients dying due to FL was higher among those ≤60 years (74%) and those with a CCI 0-1 (67%). Furthermore, 10-year excess mortality (survival reduction) was more prominent for patients >70 years (30%) and those with a CCI ≥2 (32%). Patients with a CCI ≥2 also had a higher incidence of SM. These data encourage a comprehensive pre-treatment evaluation and a tailored therapeutic approach for all FL patients.
Identifiants
pubmed: 33629152
doi: 10.1007/s00277-021-04470-7
pii: 10.1007/s00277-021-04470-7
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1231-1239Subventions
Organisme : Fundación Española de Hematología y Hemoterapia
ID : Becas de Investigación 2018
Organisme : Instituto de Salud Carlos III
ID : PI19/00925
Organisme : Instituto de Salud Carlos III
ID : PI19/00887
Références
Swerdlow SH, Campo E, Harris NL et al (2017) WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon, France
Mozas P, Nadeu F, Rivas-Delgado A, Rivero A, Garrote M, Balagué O, González-Farré B, Veloza L, Baumann T, Giné E, Delgado J, Villamor N, Campo E, Magnano L, López-Guillermo A (2020) Patterns of change in treatment, response, and outcome in patients with follicular lymphoma over the last four decades: a single-center experience. Blood Cancer J 10:1–9. https://doi.org/10.1038/s41408-020-0299-0
doi: 10.1038/s41408-020-0299-0
Bachy E, Seymour JF, Feugier P, Offner F, López-Guillermo A, Belada D, Xerri L, Catalano JV, Brice P, Lemonnier F, Martin A, Casasnovas O, Pedersen LM, Dorvaux V, Simpson D, Leppa S, Gabarre J, da Silva MG, Glaisner S, Ysebaert L, Vekhoff A, Intragumtornchai T, le Gouill S, Lister A, Estell JA, Milone G, Sonet A, Farhi J, Zeuner H, Tilly H, Salles G (2019) Sustained progression-free survival benefit of rituximab maintenance in patients with follicular lymphoma: long-term results of the PRIMA study. J Clin Oncol 37:2815–2824. https://doi.org/10.1200/JCO.19.01073
doi: 10.1200/JCO.19.01073
pubmed: 31339826
pmcid: 6823890
Junlén HR, Peterson S, Kimby E, Lockmer S, Lindén O, Nilsson-Ehle H, Erlanson M, Hagberg H, Rådlund A, Hagberg O, Wahlin BE (2015) Follicular lymphoma in Sweden: nationwide improved survival in the rituximab era, particularly in elderly women: a Swedish Lymphoma Registry Study. Leukemia 29:668–676. https://doi.org/10.1038/leu.2014.251
doi: 10.1038/leu.2014.251
pubmed: 25151959
Solal-Céligny P, Roy P, Colombat P, White J, Armitage JO, Arranz-Saez R, Au WY, Bellei M, Brice P, Caballero D, Coiffier B, Conde-Garcia E, Doyen C, Federico M, Fisher RI, Garcia-Conde JF, Guglielmi C, Hagenbeek A, Haïoun C, LeBlanc M, Lister AT, Lopez-Guillermo A, McLaughlin P, Milpied N, Morel P, Mounier N, Proctor SJ, Rohatiner A, Smith P, Soubeyran P, Tilly H, Vitolo U, Zinzani PL, Zucca E, Montserrat E (2004) Follicular lymphoma international prognostic index. Blood 104:1258–1265. https://doi.org/10.1182/blood-2003-12-4434
doi: 10.1182/blood-2003-12-4434
pubmed: 15126323
Federico M, Bellei M, Marcheselli L, Luminari S, Lopez-Guillermo A, Vitolo U, Pro B, Pileri S, Pulsoni A, Soubeyran P, Cortelazzo S, Martinelli G, Martelli M, Rigacci L, Arcaini L, di Raimondo F, Merli F, Sabattini E, McLaughlin P, Solal-Céligny P (2009) Follicular lymphoma international prognostic index 2: a new prognostic index for follicular lymphoma developed by the international follicular lymphoma prognostic factor project. J Clin Oncol 27:4555–4562. https://doi.org/10.1200/JCO.2008.21.3991
doi: 10.1200/JCO.2008.21.3991
pubmed: 19652063
Pastore A, Jurinovic V, Kridel R, Hoster E, Staiger AM, Szczepanowski M, Pott C, Kopp N, Murakami M, Horn H, Leich E, Moccia AA, Mottok A, Sunkavalli A, van Hummelen P, Ducar M, Ennishi D, Shulha HP, Hother C, Connors JM, Sehn LH, Dreyling M, Neuberg D, Möller P, Feller AC, Hansmann ML, Stein H, Rosenwald A, Ott G, Klapper W, Unterhalt M, Hiddemann W, Gascoyne RD, Weinstock DM, Weigert O (2015) Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry. Lancet Oncol 16:1111–1122. https://doi.org/10.1016/S1470-2045(15)00169-2
doi: 10.1016/S1470-2045(15)00169-2
pubmed: 26256760
Bachy E, Maurer MJ, Habermann TM, Gelas-Dore B, Maucort-Boulch D, Estell JA, van den Neste E, Bouabdallah R, Gyan E, Feldman AL, Bargay J, Delmer A, Slager SL, Gomes da Silva M, Fitoussi O, Belada D, Maisonneuve H, Intragumtornchai T, Ansell SM, Lamy T, Dartigues P, Link BK, Seymour JF, Cerhan JR, Salles G (2018) A simplified scoring system in de novo follicular lymphoma treated initially with immunochemotherapy. Blood 132:49–58. https://doi.org/10.1182/blood-2017-11-816405
doi: 10.1182/blood-2017-11-816405
pubmed: 29666118
pmcid: 6034646
Maartense E, Le Cessie S, Kluin-Nelemans HC et al (2002) Age-related differences among patients with follicular lymphoma and the importance of prognostic scoring systems: analysis from a population-based non-Hodgkin’s lynphoma registry. Ann Oncol 13:1275–1284. https://doi.org/10.1093/annonc/mdf198
doi: 10.1093/annonc/mdf198
pubmed: 12181252
Nabhan C, Aschebrook-Kilfoy B, Chiu BCH, Kruczek K, Smith SM, Evens AM (2014) The impact of race, age, and sex in follicular lymphoma: a comprehensive SEER analysis across consecutive treatment eras. Am. J. Hematol. 89:633–638
doi: 10.1002/ajh.23708
Flowers C, Ou F-S, Shi Q, Hoster E, Peterson BA, Hochster HS, Brice P, Ladetto M, Hiddemann W, Marcus RE, Kimby E, Herold M, de Bedout S, Nielsen T, Morschhauser F, Rummel M, Hagenbeek A, Vitolo U, Salles GA, Sargent D (2016) Outcomes for elderly patients (pts) with follicular lymphoma (FL) using individual patient data (IPD) from 5922 pts in 18 randomized controlled trials (RCTs): a Follicular Lymphoma Analysis of Surrogate Hypothesis (FLASH) group study. Blood 128:1102–1102. https://doi.org/10.1182/blood.v128.22.1102.1102
doi: 10.1182/blood.v128.22.1102.1102
Albarmawi H, Onukwugha E, Keating KN, Appukkuttan S, Yared J (2020) Survival benefit associated with treating follicular lymphoma in patients 80 years or older. J Geriatr Oncol 11:55–61. https://doi.org/10.1016/j.jgo.2019.10.003
doi: 10.1016/j.jgo.2019.10.003
pubmed: 31706831
Mihaljevic B, Jelicic J, Andjelic B, Antic D, Markovic O, Petkovic I, Jovanovic MP, Trajkovic G, Bila J, Djurasinovic V, Sretenovic A, Vukovic V, Smiljanic M, Balint MT (2016) FCG (FLIPI, Charlson comorbidity index, and histological grade) score is superior to FLIPI in advanced follicular lymphoma. Int J Hematol 104:692–699. https://doi.org/10.1007/s12185-016-2099-7
doi: 10.1007/s12185-016-2099-7
pubmed: 27714586
Sarkozy C, Maurer MJ, Link BK, Ghesquieres H, Nicolas E, Thompson CA, Traverse-Glehen A, Feldman AL, Allmer C, Slager SL, Ansell SM, Habermann TM, Bachy E, Cerhan JR, Salles G (2019) Cause of death in follicular lymphoma in the first decade of the rituximab era: a pooled analysis of French and US cohorts. J Clin Oncol 37:144–152. https://doi.org/10.1200/JCO.18.00400
doi: 10.1200/JCO.18.00400
pubmed: 30481079
Brice P, Bastion Y, Lepage E, Brousse N, Haïoun C, Moreau P, Straetmans N, Tilly H, Tabah I, Solal-Céligny P (1997) Comparison in low-tumor-burden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon alfa: a randomized study from the Groupe d’Etude des Lymphomes Folliculaires. J Clin Oncol 15:1110–1117. https://doi.org/10.1200/JCO.1997.15.3.1110
doi: 10.1200/JCO.1997.15.3.1110
pubmed: 9060552
Charlson ME, Pompei P, Ales KL, MacKenzie CR (1987) A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40:373–383. https://doi.org/10.1016/0021-9681(87)90171-8
doi: 10.1016/0021-9681(87)90171-8
Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ, Coiffier B, Fisher RI, Hagenbeek A, Zucca E, Rosen ST, Stroobants S, Lister TA, Hoppe RT, Dreyling M, Tobinai K, Vose JM, Connors JM, Federico M, Diehl V, International Harmonization Project on Lymphoma (2007) Revised response criteria for malignant lymphoma. J. Clin. Oncol. 25:579–586
doi: 10.1200/JCO.2006.09.2403
University of California, Berkeley (USA) and MPI for DR (Germany) (2019) Human Mortality Database. Available at www.mortality.org
Gray RJ (1988) A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat 16:1141–1154. https://doi.org/10.1214/aos/1176350951
doi: 10.1214/aos/1176350951
Alig S, Jurinovic V, Pastore A, Bararia D, Häbe S, Hellmuth JC, Kridel R, Gascoyne R, Schmidt C, Zöllner AK, Buske C, Dreyling M, Unterhalt M, Hiddemann W, Hoster E, Weigert O (2018) Impact of age on genetics and treatment efficacy in follicular lymphoma. Haematologica 103:e364–e367
doi: 10.3324/haematol.2018.187773